Allan Jonathan, General Counsel and Corporate Secretary at Stoke Therapeutics ($STOK), sold about $1.54 million in company shares across nineteen open market transactions over the past year. His most recent sale occurred on December 8, 2025. These sales rank 4,000th among 11,678 individual insiders, below the average of $8.59 million per seller and 6.4 transactions. He made no open market purchases in this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 20, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 601 | $34.41 | 19,543.0000 | 60,397,681 | 2.98% | 0.00% |
| March 20, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 8692 | $33.64 | 20,144.0000 | 60,397,681 | 30.14% | 0.01% |
| March 17, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1791 | $33.38 | 33,464.0000 | 60,397,681 | 5.08% | 0.00% |
| March 18, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 334 | $31.79 | 28,908.0000 | 60,397,681 | 1.14% | 0.00% |
| March 18, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 72 | $32.85 | 28,836.0000 | 60,397,681 | 0.25% | 0.00% |
| March 18, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 4222 | $31.28 | 29,242.0000 | 60,397,681 | 12.62% | 0.01% |
| March 17, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 2476 | $32.74 | 35,255.0000 | 60,397,681 | 6.56% | 0.00% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 12000 | $0.00 | 37,731.0000 | 60,397,681 | 46.64% | 0.02% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 12000 | $0.00 | 36,000.0000 | 60,397,681 | 25.00% | 0.02% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 6000 | $0.00 | 12,000.0000 | 60,397,681 | 33.33% | 0.01% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 7475 | $0.00 | 7,475.0000 | 60,397,681 | 50.00% | 0.01% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 7475 | $0.00 | 19,731.0000 | 60,397,681 | 60.99% | 0.01% |
| March 15, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 6000 | $0.00 | 25,731.0000 | 60,397,681 | 30.41% | 0.01% |
| Feb. 17, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Employee Stock Option (Right to Buy) | 53000 | $0.00 | 53,000.0000 | 60,397,681 | 9999.99% | 0.09% |
| Feb. 17, 2026 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Restricted Stock Units | 35000 | $0.00 | 35,000.0000 | 60,397,681 | 9999.99% | 0.06% |
| Dec. 8, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 2678 | $32.61 | 11,831.0000 | 60,397,681 | 18.46% | 0.00% |
| Dec. 8, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1300 | $31.60 | 14,509.0000 | 60,397,681 | 8.22% | 0.00% |
| Dec. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 6000 | $0.00 | 25,612.0000 | 60,397,681 | 30.59% | 0.01% |
| Dec. 4, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 824 | $30.76 | 24,788.0000 | 60,397,681 | 3.22% | 0.00% |
| Dec. 4, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 194 | $31.32 | 24,594.0000 | 60,397,681 | 0.78% | 0.00% |
| Dec. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Performance Stock Units | 6000 | $0.00 | 0.0000 | 60,397,681 | 100.00% | 0.01% |
| Dec. 5, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1004 | $31.33 | 23,590.0000 | 60,397,681 | 4.08% | 0.00% |
| Dec. 5, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 5437 | $31.08 | 18,153.0000 | 60,397,681 | 23.05% | 0.01% |
| Dec. 5, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 2344 | $31.76 | 15,809.0000 | 60,397,681 | 12.91% | 0.00% |
| Dec. 1, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 12357 | $0.00 | 0.0000 | 60,397,681 | 100.00% | 0.02% |
| Dec. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 898 | $30.34 | 21,006.0000 | 60,397,681 | 4.10% | 0.00% |
| Dec. 2, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 868 | $30.14 | 21,904.0000 | 60,397,681 | 3.81% | 0.00% |
| Dec. 2, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1416 | $29.56 | 22,772.0000 | 60,397,681 | 5.85% | 0.00% |
| Dec. 1, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 12357 | $0.00 | 24,188.0000 | 60,397,681 | 104.45% | 0.02% |
| Dec. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1394 | $30.85 | 19,612.0000 | 60,397,681 | 6.64% | 0.00% |
| Oct. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 10000 | $25.07 | 11,831.0000 | 60,397,681 | 45.81% | 0.02% |
| Oct. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Stock Option (Right to Buy) | 10000 | $0.00 | 34,800.0000 | 60,397,681 | 22.32% | 0.02% |
| Oct. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 10000 | $9.15 | 21,831.0000 | 60,397,681 | 84.52% | 0.02% |
| Aug. 29, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 850 | $20.00 | 23,948.0000 | 54,008,883 | 3.43% | 0.00% |
| Aug. 29, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 850 | $7.07 | 24,798.0000 | 54,008,883 | 3.55% | 0.00% |
| Sept. 2, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 9150 | $7.07 | 33,098.0000 | 54,008,883 | 38.21% | 0.02% |
| Sept. 2, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 14922 | $20.14 | 18,176.0000 | 54,008,883 | 45.08% | 0.03% |
| Sept. 3, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 6345 | $20.07 | 11,831.0000 | 54,008,883 | 34.91% | 0.01% |
| Aug. 29, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Stock Option (Right to Buy) | 850 | $0.00 | 24,951.0000 | 54,008,883 | 3.29% | 0.00% |
| Sept. 2, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Stock Option (Right to Buy) | 9150 | $0.00 | 15,801.0000 | 54,008,883 | 36.67% | 0.02% |
| Aug. 18, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1683 | $18.24 | 23,948.0000 | 54,008,883 | 6.57% | 0.00% |
| Aug. 14, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Performance Stock Units | 6000 | $0.00 | 6,000.0000 | 54,008,883 | 50.00% | 0.01% |
| Aug. 14, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Performance Stock Units | 12000 | $0.00 | 12,000.0000 | 54,008,883 | 9999.99% | 0.02% |
| Aug. 14, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 6000 | $0.00 | 25,631.0000 | 54,008,883 | 30.56% | 0.01% |
| Aug. 13, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 13712 | $15.00 | 19,631.0000 | 54,008,883 | 41.12% | 0.03% |
| March 18, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 2266 | $8.67 | 33,510.0000 | 54,008,883 | 6.33% | 0.00% |
| March 20, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Employee Stock Option (Right to Buy) | 72000 | $0.00 | 72,000.0000 | 54,008,883 | 9999.99% | 0.13% |
| March 19, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1945 | $8.27 | 31,565.0000 | 54,008,883 | 5.80% | 0.00% |
| March 20, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Restricted Stock Units | 48000 | $0.00 | 48,000.0000 | 54,008,883 | 9999.99% | 0.09% |
| March 15, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 7475 | $0.00 | 29,776.0000 | 54,008,883 | 33.52% | 0.01% |
| March 15, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 6000 | $0.00 | 18,000.0000 | 54,008,883 | 25.00% | 0.01% |
| March 15, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 7475 | $0.00 | 14,950.0000 | 54,008,883 | 33.33% | 0.01% |
| March 15, 2025 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 6000 | $0.00 | 35,776.0000 | 54,008,883 | 20.15% | 0.01% |
| Dec. 9, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 1552 | $12.99 | 21,476.0000 | 56,341,074 | 6.74% | 0.00% |
| Dec. 9, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 12114 | $13.69 | 23,028.0000 | 56,341,074 | 34.47% | 0.02% |
| Dec. 6, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 9696 | $12.78 | 35,142.0000 | 56,341,074 | 21.62% | 0.02% |
| Dec. 3, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Performance Stock Units | 6000 | $0.00 | 6,000.0000 | 56,341,074 | 50.00% | 0.01% |
| Dec. 3, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Performance Stock Units | 12000 | $0.00 | 12,000.0000 | 56,341,074 | 9999.99% | 0.02% |
| Dec. 3, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 6000 | $0.00 | 44,838.0000 | 56,341,074 | 15.45% | 0.01% |
| Dec. 1, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Unit (RSU) | 33927 | $0.00 | 12,357.0000 | 56,341,074 | 73.30% | 0.06% |
| Dec. 1, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 33927 | $0.00 | 38,838.0000 | 56,341,074 | 690.84% | 0.06% |
| March 27, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Restricted Stock Units | 24000 | $0.00 | 24,000.0000 | 43,994,862 | 9999.99% | 0.05% |
| March 27, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | A | Employee Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 43,994,862 | 9999.99% | 0.08% |
| May 20, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Stock Option (Right to Buy) | 8599 | $0.00 | 25,801.0000 | 43,994,862 | 25.00% | 0.02% |
| May 20, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 8599 | $7.07 | 11,197.0000 | 43,994,862 | 330.99% | 0.02% |
| May 20, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 8599 | $15.04 | 2,598.0000 | 43,994,862 | 76.80% | 0.02% |
| March 28, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 100 | $13.81 | 2,598.0000 | 43,994,862 | 3.71% | 0.00% |
| March 28, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 5026 | $13.19 | 2,698.0000 | 43,994,862 | 65.07% | 0.01% |
| March 19, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | S | Common Stock | 2349 | $6.10 | 7,724.0000 | 43,994,862 | 23.32% | 0.01% |
| March 15, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Common Stock | 7475 | $0.00 | 10,073.0000 | 43,994,862 | 287.72% | 0.02% |
| March 15, 2024 | Stoke Therapeutics, Inc. | $STOK | Allan Jonathan | GENERAL COUNSEL & CORP SEC | M | Restricted Stock Units | 7475 | $0.00 | 22,425.0000 | 43,994,862 | 25.00% | 0.02% |